Developer docs
API playgroundTry for free, no card

Search company profiles

Endogenex

Full company profile

uuid0000tnh

Namestring
Endogenex
Legal namestring
Endogenex, Inc.
Websiteurl
endogenex.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that delivers non-thermal pulsed electric fields (PEF) to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells for the treatment of type 2 diabetes. The company targets adults with type 2 diabetes whose blood glucose is inadequately controlled by existing glucose-lowering medications, an addressable population of more than 400 million people globally. Its core technology consists of a specialized catheter-based endoscopic delivery system that applies controlled electrical pulses to disrupt poorly functioning cells and induce regeneration, with a second-generation dose-response catheter design demonstrating a clear dose-metabolic response relationship in the 48-week REGENT-1 study (mean HbA1c reduction of 1.5%, fasting plasma glucose reduction of 2.3 mmol/L, body weight loss of 5.4 kg at the highest treatment intensity, with 100% procedural technical success and no device-related serious adverse events).

The company was founded in 2002 in partnership with Mayo Clinic and is headquartered in Plymouth, Minnesota. Endogenex has received FDA Breakthrough Device Designation and FDA Investigational Device Exemption approval for the ReCET pivotal study, a multicenter, prospective, randomized, double-blinded, sham-controlled trial enrolling up to 350 patients at approximately 40 sites in the United States and Australia, with first patient enrolled in October 2024. The company's expected business model is medical device hardware sales targeting gastroenterologists, endocrinologists, and diabetes specialists at hospitals and ambulatory surgery centers, although the product is currently investigational and not for sale in any geography. The company is privately held and has raised approximately $162.9 million in total documented funding, including a $138 million Series C financing completed across two rounds ($88M in June 2024 and a $50M extension in March 2026 led by Arboretum Ventures).

Short descriptiontext

Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that uses non-thermal pulsed electric fields to regenerate duodenal signaling cells and treat type 2 diabetes in adults with inadequately controlled blood glucose.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlymouth, United States
HQ citystring
Plymouth
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endoscopic medical devices, diabetes treatment technology, pulsed electric field therapy, duodenal tissue ablation, metabolic disease intervention
Industry2 codes
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKADAA
Diabetes (General)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Endoscopic Medical Devices for Metabolic Disease
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Future)
TypeHardware Sales
Description

Endogenex is a clinical-stage medical technology company developing the pulsENDO system for type 2 diabetes treatment. Once FDA approved, the company intends to commercialize its endoscopic procedure as a treatment option for patients with inadequately controlled type 2 diabetes. The product is described as investigational and not for sale in any geography as of the current date.

endogenex.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Endogenex is developing the pulsENDO System, a catheter-based endoscopic medical device that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum. The procedure targets poorly functioning signaling cells to induce regeneration of healthy cells, with the goal of restoring metabolic function and helping patients with type 2 diabetes regain control of their blood glucose levels. The system is investigational, not yet approved for commercial sale, and is being evaluated in the pivotal ReCET Clinical Study for FDA approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Mean HbA1c reduction of 1.5% at 48 weeks with highest treatment intensity
+6 more records
Product overview1 text field

Endogenex offers the pulsENDO System as its core product technology, which uses non-thermal pulsed electric fields delivered via a specialized catheter through an endoscopic procedure to treat inflamed duodenal tissue. The ReCET System represents the clinical study application of this technology. The pulsENDO catheter is inserted through the mouth into the duodenum where it delivers controlled electrical pulses to regenerate healthy cells. Both products work as a unified system—the pulsENDO is the technology platform while ReCET is the branded clinical application being evaluated in pivotal trials. The system is investigational and not yet approved for commercial sale.

Product and service2 records
1pulsENDO System
CategoryEndoscopic medical device / Metabolic disease treatment platform
Description

An endoscopic system that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells and restore metabolic function. It is intended as a single outpatient procedure for adults with type 2 diabetes inadequately controlled by glucose-lowering medications. The system is investigational, limited by federal law to investigational use, and not for sale in any geography.

2ReCET System (Recellularization of Enterocrine Tissues)
CategoryEndoscopic medical device / Pivotal clinical study application
Description

The clinical branded application of the pulsENDO technology, evaluated in the pivotal ReCET Clinical Study. The ReCET System is being assessed for safety and effectiveness in adult patients with type 2 diabetes inadequately controlled by non-insulin, glucose-lowering medications at up to 40 sites in the United States and Australia, enrolling approximately 350 patients.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Endogenex was founded in partnership with Mayo Clinic. Mayo Clinic provides clinical expertise, research collaboration, and co-development of the technology. Dr. Barham Abu Dayyeh from Mayo Clinic serves as Co-inventor and Co-Principal Investigator for the ReCET Study. Mayo Clinic is also an investor in the company.

2Cuyuna Regional Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site where Dr. Paul Severson serves as clinical investigator and has provided endorsement of the pulsENDO procedure as a treatment opportunity for type 2 diabetes patients.

endogenex.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fractyl Health is the most direct competitor to Endogenex, developing Revita (Duodenal Mucosal Resurfacing), a catheter-based endoscopic procedure that ablates the duodenal mucosa to treat T2D. Both companies target duodenal tissue regeneration as a root-cause T2D therapy using endoscopic catheter delivery systems.

TypeEmerging player
Description

Allurion develops the Allurion Balloon, a swallowable, endoscopy-free gastric balloon for weight loss. It is comparable to Endogenex as a procedural, non-pharmacologic metabolic intervention targeting obesity-related metabolic disease with a similar outpatient, single-procedure commercial model.

TypeBroad incumbent
Description

Medtronic is a major diabetes device incumbent with insulin pumps, CGM-adjacent products, and a large diabetes sales force. While Endogenex targets a different mechanism (procedural duodenal intervention vs. insulin delivery), Medtronic represents a potential strategic acquirer and the dominant player in the diabetes device market Endogenex would enter.

TypeBroad incumbent
Description

Dexcom is the market leader in continuous glucose monitoring (CGM) for T2D and T1D management. While not a direct competitor in mechanism, Dexcom represents the dominant non-pharmacologic monitoring technology used by T2D patients, and could be a complementary or competitive technology to Endogenex's procedural therapy.

TypeBroad incumbent
Description

Insulet manufactures the Omnipod tubeless insulin pump, a major T2D and T1D management device. Like Medtronic, Insulet is an established diabetes device incumbent with deep payer coverage and prescriber relationships, representing both a strategic acquirer and a competitor for physician mindshare in T2D treatment.

TypeBroad incumbent
Description

Boston Scientific is a major endoscopic and interventional device manufacturer that acquired Apollo Endosurgery. Comparable to Endogenex as an endoscopic procedure device manufacturer with established sales channels into gastroenterology and bariatric surgery — the same specialist channels Endogenex would target commercially.

TypeBroad incumbent
Description

Olympus is the global leader in endoscopy equipment and related therapeutic devices. Comparable to Endogenex as an endoscopic procedure ecosystem player and potential strategic partner or acquirer, with established relationships across the gastroenterology specialist channel Endogenex would target.

TypeBroad incumbent
Description

Abbott Diabetes Care manufactures the FreeStyle Libre CGM, the leading CGM system globally. While not a direct mechanism competitor, Abbott represents a major incumbent in the non-pharmacologic T2D management market and a potential strategic acquirer of disruptive procedural therapies like Endogenex's pulsENDO system.

TypeEmerging player
Description

Spatz Medical develops the Spatz3 Adjustable Gastric Balloon, an endoscopic weight loss balloon. Comparable to Endogenex as a procedural endoscopic metabolic intervention with a similar single-procedure commercial model, though targeting obesity rather than T2D directly.

TypeEmerging player
Description

ReShape Lifesciences develops the Lap-Band adjustable gastric banding system and other metabolic intervention products. Comparable to Endogenex as a procedural metabolic intervention company targeting obesity-related metabolic disease with similar outpatient procedural commercial models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endogenex

Endoscopic Medical Devices for Metabolic Diseaseendogenex.com

Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that uses non-thermal pulsed electric fields to regenerate duodenal signaling cells and treat type 2 diabetes in adults with inadequately controlled blood glucose.

What Endogenex does

Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that delivers non-thermal pulsed electric fields (PEF) to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells for the treatment of type 2 diabetes. The company targets adults with type 2 diabetes whose blood glucose is inadequately controlled by existing glucose-lowering medications, an addressable population of more than 400 million people globally. Its core technology consists of a specialized catheter-based endoscopic delivery system that applies controlled electrical pulses to disrupt poorly functioning cells and induce regeneration, with a second-generation dose-response catheter design demonstrating a clear dose-metabolic response relationship in the 48-week REGENT-1 study (mean HbA1c reduction of 1.5%, fasting plasma glucose reduction of 2.3 mmol/L, body weight loss of 5.4 kg at the highest treatment intensity, with 100% procedural technical success and no device-related serious adverse events).

The company was founded in 2002 in partnership with Mayo Clinic and is headquartered in Plymouth, Minnesota. Endogenex has received FDA Breakthrough Device Designation and FDA Investigational Device Exemption approval for the ReCET pivotal study, a multicenter, prospective, randomized, double-blinded, sham-controlled trial enrolling up to 350 patients at approximately 40 sites in the United States and Australia, with first patient enrolled in October 2024. The company's expected business model is medical device hardware sales targeting gastroenterologists, endocrinologists, and diabetes specialists at hospitals and ambulatory surgery centers, although the product is currently investigational and not for sale in any geography. The company is privately held and has raised approximately $162.9 million in total documented funding, including a $138 million Series C financing completed across two rounds ($88M in June 2024 and a $50M extension in March 2026 led by Arboretum Ventures).

Endogenex firmographics

Firmographics
Name
Endogenex
Legal name
Endogenex, Inc.
Website
https://endogenex.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Endogenex is a clinical-stage medical technology company developing the pulsENDO system, an endoscopic procedure that uses non-thermal pulsed electric fields to regenerate duodenal signaling cells and treat type 2 diabetes in adults with inadequately controlled blood glucose.
Ownership category
akta.pro rank

Endogenex industry classification

Industry
Product category
Endoscopic Medical Devices for Metabolic Disease
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKADAA
Diabetes (General)

Keywords

  • Endoscopic medical devices
  • Diabetes treatment technology
  • Pulsed electric field therapy
  • Duodenal tissue ablation
  • Metabolic disease intervention

Where Endogenex is headquartered

Location

Headquarters

HQ city
Plymouth
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Endogenex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (Future): Endogenex is a clinical-stage medical technology company developing the pulsENDO system for type 2 diabetes treatment. Once FDA approved, the company intends to commercialize its endoscopic procedure as a treatment option for patients with inadequately controlled type 2 diabetes. The product is described as investigational and not for sale in any geography as of the current date.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Endogenex product offering

Product offering

Core offering

Endogenex is developing the pulsENDO System, a catheter-based endoscopic medical device that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum. The procedure targets poorly functioning signaling cells to induce regeneration of healthy cells, with the goal of restoring metabolic function and helping patients with type 2 diabetes regain control of their blood glucose levels. The system is investigational, not yet approved for commercial sale, and is being evaluated in the pivotal ReCET Clinical Study for FDA approval.

Product overview

Endogenex offers the pulsENDO System as its core product technology, which uses non-thermal pulsed electric fields delivered via a specialized catheter through an endoscopic procedure to treat inflamed duodenal tissue. The ReCET System represents the clinical study application of this technology. The pulsENDO catheter is inserted through the mouth into the duodenum where it delivers controlled electrical pulses to regenerate healthy cells. Both products work as a unified system—the pulsENDO is the technology platform while ReCET is the branded clinical application being evaluated in pivotal trials. The system is investigational and not yet approved for commercial sale.

Differentiator

Problem solved

Functional benefit

Products and services

  • pulsENDO System An endoscopic system that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum to regenerate healthy metabolic signaling cells and restore metabolic function. It is intended as a single outpatient procedure for adults with type 2 diabetes inadequately controlled by glucose-lowering medications. The system is investigational, limited by federal law to investigational use, and not for sale in any geography.
  • ReCET System (Recellularization of Enterocrine Tissues) The clinical branded application of the pulsENDO technology, evaluated in the pivotal ReCET Clinical Study. The ReCET System is being assessed for safety and effectiveness in adult patients with type 2 diabetes inadequately controlled by non-insulin, glucose-lowering medications at up to 40 sites in the United States and Australia, enrolling approximately 350 patients.

Quantifiable outcome

  • Mean HbA1c reduction of 1.5% at 48 weeks with highest treatment intensity
  • +6 more outcomes

Companies that use Endogenex

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Endogenex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Endogenex partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Mayo CliniccoreStrategic or Co-development PartnerEndogenex was founded in partnership with Mayo Clinic. Mayo Clinic provides clinical expertise, research collaboration, and co-development of the technology. Dr. Barham Abu Dayyeh from Mayo Clinic serves as Co-inventor and Co-Principal Investigator for the ReCET Study. Mayo Clinic is also an investor in the company.
  • Cuyuna Regional Medical CenterminorStrategic or Co-development PartnerClinical trial site where Dr. Paul Severson serves as clinical investigator and has provided endorsement of the pulsENDO procedure as a treatment opportunity for type 2 diabetes patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Endogenex competitors and assessment

Company assessment

Direct peers

  • Fractyl Health: Fractyl Health is the most direct competitor to Endogenex, developing Revita (Duodenal Mucosal Resurfacing), a catheter-based endoscopic procedure that ablates the duodenal mucosa to treat T2D. Both companies target duodenal tissue regeneration as a root-cause T2D therapy using endoscopic catheter delivery systems.

Emerging players

  • Allurion Technologies: Allurion develops the Allurion Balloon, a swallowable, endoscopy-free gastric balloon for weight loss. It is comparable to Endogenex as a procedural, non-pharmacologic metabolic intervention targeting obesity-related metabolic disease with a similar outpatient, single-procedure commercial model.
  • Spatz Medical: Spatz Medical develops the Spatz3 Adjustable Gastric Balloon, an endoscopic weight loss balloon. Comparable to Endogenex as a procedural endoscopic metabolic intervention with a similar single-procedure commercial model, though targeting obesity rather than T2D directly.
  • ReShape Lifesciences: ReShape Lifesciences develops the Lap-Band adjustable gastric banding system and other metabolic intervention products. Comparable to Endogenex as a procedural metabolic intervention company targeting obesity-related metabolic disease with similar outpatient procedural commercial models.

Broad incumbents

  • Medtronic: Medtronic is a major diabetes device incumbent with insulin pumps, CGM-adjacent products, and a large diabetes sales force. While Endogenex targets a different mechanism (procedural duodenal intervention vs. insulin delivery), Medtronic represents a potential strategic acquirer and the dominant player in the diabetes device market Endogenex would enter.
  • Dexcom: Dexcom is the market leader in continuous glucose monitoring (CGM) for T2D and T1D management. While not a direct competitor in mechanism, Dexcom represents the dominant non-pharmacologic monitoring technology used by T2D patients, and could be a complementary or competitive technology to Endogenex's procedural therapy.
  • Insulet: Insulet manufactures the Omnipod tubeless insulin pump, a major T2D and T1D management device. Like Medtronic, Insulet is an established diabetes device incumbent with deep payer coverage and prescriber relationships, representing both a strategic acquirer and a competitor for physician mindshare in T2D treatment.
  • Boston Scientific: Boston Scientific is a major endoscopic and interventional device manufacturer that acquired Apollo Endosurgery. Comparable to Endogenex as an endoscopic procedure device manufacturer with established sales channels into gastroenterology and bariatric surgery — the same specialist channels Endogenex would target commercially.
  • Olympus Corporation: Olympus is the global leader in endoscopy equipment and related therapeutic devices. Comparable to Endogenex as an endoscopic procedure ecosystem player and potential strategic partner or acquirer, with established relationships across the gastroenterology specialist channel Endogenex would target.
  • Abbott Diabetes Care: Abbott Diabetes Care manufactures the FreeStyle Libre CGM, the leading CGM system globally. While not a direct mechanism competitor, Abbott represents a major incumbent in the non-pharmacologic T2D management market and a potential strategic acquirer of disruptive procedural therapies like Endogenex's pulsENDO system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Endogenex social profiles

Digital presence

Endogenex compliance and trust

Trust signal

Compliance2 records

Endogenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endogenex leadership team

Management profile

Number of profiles

Profiles9 records

Endogenex funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endogenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endogenex

What does Endogenex do?

Endogenex is developing the pulsENDO System, a catheter-based endoscopic medical device that delivers non-thermal pulsed electric fields to the mucosa and submucosa of the duodenum. The procedure targets poorly functioning signaling cells to induce regeneration of healthy cells, with the goal of restoring metabolic function and helping patients with type 2 diabetes regain control of their blood glucose levels. The system is investigational, not yet approved for commercial sale, and is being evaluated in the pivotal ReCET Clinical Study for FDA approval.

Is Endogenex a public or private company?

Endogenex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Endogenex founded?

Endogenex was founded in 2002. It employs 11 to 50 people.

Where is Endogenex based?

Endogenex is headquartered in Plymouth, United States, in the North America region.

How does Endogenex make money?

One revenue line is on record: medical Device Sales (Future).

Who are Endogenex's main competitors?

Fractyl Health is listed as a direct peer. Emerging players are Allurion Technologies, Spatz Medical and ReShape Lifesciences. Broad incumbents are Medtronic, Dexcom, Insulet, Boston Scientific, Olympus Corporation and Abbott Diabetes Care.

Does Endogenex have an API?

No public API is recorded for Endogenex.

What industry is Endogenex in?

Endogenex's product category is Endoscopic Medical Devices for Metabolic Disease. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser), with a secondary code of HLAKADAA, Diabetes (General). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceUPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical StudyEndogenex announced full enrollment of 350 patients in the ReCET Clinical Study across 40 sites in the US and Australia. The study assesses the Endogenex System's safety and effectiveness for type 2 diabetes, with primary endpoint measuring HbA1c change at six months. Results could advance FDA approval of the novel endoscopic treatment.GlobeNewswireUPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical StudyEndogenex, a clinical-stage medical device company focused on type 2 diabetes, announced full enrollment of its ReCET Clinical Study with 350 patients across approximately 40 clinical sites in the United States and Australia. The multicenter, randomized, double-blinded, sham-controlled trial is evaluating the Endogenex System, a novel endoscopic procedure using non-thermal pulsed electric fields to target duodenal dysfunction and improve glycemic control, with the primary endpoint measuring HbA1c change at six months. With enrollment complete, the company will now focus on patient follow-up through the 12-month observation period, with results potentially opening a new approach to type 2 diabetes treatment beyond pharmacotherapy.MassDeviceEndogenex completes enrollment in trial of endoscopic diabetes treatmentMinneapolis-based Endogenex announced completion of enrollment in its ReCET clinical study, reaching 350 patients across approximately 40 clinical sites in the U.S. and Australia to evaluate the Endogenex System's safety and effectiveness in type 2 diabetes patients with inadequately controlled blood glucose. The endoscopic treatment uses electroporation therapy with non-thermogenic pulsed electric fields to regenerate duodenal mucosal and submucosal cells, targeting the gut as an unmet treatment pathway. The company, which recently raised $50 million to support its efforts, will now focus on follow-up through the six-month primary endpoint and full 12-month observation period, with results potentially opening a new approach to diabetes care.GlobeNewswireEndogenex Announces Full Enrollment of the ReCET Clinical StudyEndogenex announced the full enrollment of 350 patients in its ReCET clinical study, a randomized trial assessing the safety and effectiveness of its duodenal treatment system for type 2 diabetes. The multicenter study is conducted across approximately 40 sites in the United States and Australia and will follow participants for 12 months to measure HbA1c changes. This milestone marks a transition from recruitment to data collection for the company's novel endoscopic therapy.JixinXiaochuang Medical completes Angel + round financing, becoming the first in the country to enter the non-thermal ablation DMR innovative therapy for metabolic diseases.Xiaochuang Medical completed an angel round + financing led by Yuanhe Holdings, becoming the first in China to enter non-thermal ablation DMR therapy for metabolic diseases. The funds will advance clinical trials and commercialization, and the company recently performed the first nationwide pulse electric field duodenal mucosal reconstruction surgery on a type 2 diabetes patient.Pulse 2.0Endogenex: $50 Million Raised For Type 2 Diabetes Treatment TechnologyEndogenex, a clinical-stage medical technology company, closed a $50 million Series C extension round led by Arboretum Ventures, bringing total Series C funding to $138 million. The capital will fund completion of the ReCET Clinical Study and support the regulatory pathway toward FDA approval for the company's type 2 diabetes treatment. The technology is a minimally invasive endoscopic procedure using non-thermal pulsed electric fields to target the duodenum, with trials being conducted at sites in the United States and Australia.American City Business JournalsEndogenex raises $50M for diabetes device clinical trialsEndogenex, a medical technology manufacturer based in Plymouth, Minnesota, has raised $50 million to fund clinical trials for its type 2 diabetes treatment device. The funding supports the company as it moves its pioneered treatment into the trial phase.FinSMEsEndogenex Raises $50M in Series C Extension FundingEndogenex, a Minneapolis-based clinical-stage medical technology company, has raised $50 million in Series C extension funding, bringing its total Series C financing to $138 million. The round was led by Arboretum Ventures with participation from existing investors. The company plans to use the funds to expand operations and advance R&D efforts for its Endogenex System, a minimally invasive procedure using pulsed electric fields to treat duodenal inflammation associated with type 2 diabetes.FierceBiotechEndogenex nets $50M to carry intestinal diabetes procedure to the FDAEndogenex has raised $50 million in venture capital financing to complete development of its minimally invasive pulsed electric field procedure for Type 2 diabetes and advance it toward FDA approval. Initial clinical study results showed the treatment achieved a 100% technical success rate, with a group of 31 patients receiving a higher-energy device showing an average HbA1c reduction of 1.5 percentage points and weight loss of about 5.4 kilograms over 48 weeks. The funding, led by new backer Arboretum Ventures as an extension to the 2024 series C round, will support the company's pivotal ReCET trial that is now enrolling patients.Medical Device NetworkEndogenex raises $50m to advance type 2 diabetes treatmentEndogenex has raised $50m in a Series C extension financing round, led by new investor Arboretum Ventures with participation from existing investors, to complete a pivotal trial of its ReCET endoscopic treatment for type 2 diabetes and support an FDA regulatory filing. The funding brings the company's total Series C to $138m and total capital raised to $1bn since its founding in 2002. The Minnesota-based company's ReCET system uses non-thermal pulsed electric fields to target duodenum tissue inflammation believed to contribute to the root cause of type 2 diabetes.